Changes in end organ function were assessed in 59 pts having a continuous flow LVAD in place for more than 3 years. Renal and hepatic function improved initially, but renal function deteriorated to preoperative levels during the follow-up period.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Heart Failure
March 5, 2017
February 15, 2017
The authors reviewed the retrospective INTERMACS database to assess whether outcomes after continuous-flow (CF) LVAD implantation varied with patient BSA. A total of over 10,000 CF LVAD patients were included. Of these, 231 (2%) had a BSA < 1.5 m².
January 13, 2017
With the everpresent question of potentially extending LVAD therapy to ambulatory patients with advanced heart failure, the authors--using a Markov model--projected the incremental cost-efffectiveness ratio (ICER) of DT LVADs in this population as compared to conventional medical therapy.
November 1, 2016
An interesting case series of cardiotoxicity of modern chemotherapy attempting to elucidate mechanisms of heart failure.
July 18, 2016
A handy mini-textbook on ECMO
June 25, 2016
A large retrospective study of the UNOS database advances that elevated troponin I in selected cardiac donors is NOT associated with various adverse events. The conclusion is likely to stimulate heated discussions.
May 21, 2016
This review provides an excellent summary of patient outcomes following LVAD explantation. The authors review 11 studies comprosing of 213 patients and conclude that excellent 10 year survival outcomes can be maintained after LVAD explantation in carefully selected patients.
April 28, 2016
Stephen Westaby reflects on his extraordinary career in cardiac surgery in an interview with Leanne Harling, which was filmed at the 2015 EACTS Annual Meeting in Amsterdam, the Netherlands.
April 23, 2016
An editorial discussion of the impressive 10-year benefits of CABG for ischemic cardiomyopathy as found in the STICH trial.
March 31, 2016
A commentary and follow-up comment on last year's ERICCA and RIPHeart- related publications in the NEJM.